Science Corp's PRIMA Chip Restores Vision, Raises $230M
Tech News Today | 2 Min News | The Daily News Now! · The Daily News Now!
Audio is streamed directly from the publisher (api.fastcast.ai) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Max Hodaks Science Corporation, formerly Neuralink, has raised $230M in a Series C round, valuing it at $1.25B. Their key product, PRIMA, a tiny chip implanted in the eye, has shown promising results in clinical trials, with 80% of patients gaining enough vision to read. Science is set to launch PRIMA in Europe by mid-2026 and is expanding trials to other conditions. The funding will also support their work on brain surface interfaces and a new organ preservation system.
Support the show:
Get a discount at https://solipillow.com/discount/dnn.
Advertise on DNN:
[email protected]
This is an automated, high-level news summary based on public reporting.
Report issues to [email protected].
View sources & latest updates:
https://sources.thednn.ai/0814dbf3a725ae2f